Opinion
Video
INTRIGUE Trial: Key Findings in Second-Line Setting
Author(s):
Experts discuss the key findings from the INTRIGUE trial comparing ripretinib to sunitinib in the second-line setting, focusing on efficacy endpoints like progression-free survival (PFS) and PFS on next line of therapy, and interpret the patient-reported outcome (PRO) and tolerability data reported in the study.
Video content above is prompted by the following:
- Please walk us through the key findings from the INTRIGUE trial comparing ripretinib to sunitinib in the second-line setting. What were the key efficacy end points evaluated in this study, and how did ripretinib perform compared to sunitinib on measures like PFS and PFS on next line of therapy? How do you interpret the PRO and tolerability data reported from INTRIGUE?
Latest CME
View All
Video
Addressing Unmet Needs in HER2+ Metastatic BTC
Apr 18th 2025 - Apr 19th 2026
online-activity
Video
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Apr 17th 2025 - May 23rd 2025
online-activity
Video
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Apr 17th 2025 - May 23rd 2025
online-activity
Related Content
.png?fit=crop&auto=format)
.jpg?fit=crop&auto=format)
